

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number  
**WO 03/059255 A2**

(51) International Patent Classification<sup>7</sup>:

**A61K**

(74) Agent: **WOLFFE, Susan, A.**; Banner & Witcoff, Ltd.,  
1001 G Street, N.W., Washington, DC 20001-4597 (US).

(21) International Application Number: **PCT/US02/40748**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(22) International Filing Date:

20 December 2002 (20.12.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/341,867 21 December 2001 (21.12.2001) US

(71) Applicant (*for all designated States except US*): **GUILFORD PHARMACEUTICALS, INC.** [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BONNEVILLE, George** [US/US]; 5711 Greenleaf Road, Baltimore, MD 21210 (US). **DELAHANTY, Greg** [US/US]; 22 Enchanted Hills Road, Apt. 203, Owings Mills, MD 21117 (US). **WALZ, Andrew, J.** [US/US]; 122 Morgan Elis Way, Baltimore, MD 21206 (US).

Published:

— without international search report and to be republished upon receipt of that report


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR PREPARING WATER-SOLUBLE PHOSPHONOXYMETHYL DERIVATIVES OF ALCOHOL AND PHENOL

First Step



Second Step



**WO 03/059255 A2**

(57) Abstract: A process for making water-soluble phosphonoxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A. In particular, the process for preparing water-soluble phosphonoxymethyl derivatives comprises the steps of Formula (i) and Formula (ii); R-OH represents an alcohol- or phenol-containing drug, n represents an integer of 1 or 2, R<sup>1</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation, and R<sup>2</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation.

**PROCESS FOR PREPARING WATER-SOLUBLE PHOSPHONOOXYMETHYL  
DERIVATIVES OF ALCOHOL AND PHENOL**

- [01] This application claims priority to U.S. Provisional Application 60/341,867 filed December 21, 2001, which is hereby incorporated by reference in its entirety.

**FIELD OF THE INVENTION**



- [02] The present invention relates to a novel process for preparing water-soluble prodrugs of aromatic hindered hydroxyl group containing pharmaceuticals. Particularly, the present invention concerns a process for making water-soluble phosphonooxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A.


**BACKGROUND OF THE INVENTION**

- [03] The successful delivery of a pharmaceutical to a patient is of critical importance in the treatment of disorders. However, the use of many clinical drugs with known properties is limited by their very low water solubility. As a result of low water solubility these drugs must be formulated in co-solvent pharmaceutical vehicles, including surfactants. These surfactants have been shown to lead to severe side effects in humans that limit the clinical safety of these drugs and therefore the treatment of several disorders.
- [04] For example, camptothecin is a natural product isolated from barks of the Chinese camptotheca tree, *Camptotheca accuminata*. It has been shown to have strong anti-tumor activity in several *in vivo* animal models including major tumor types such as lung, breast, ovary, pancreas, colon and stomach cancer and malignant melanoma. The serious drawback of camptothecin is its very limited water solubility. For biological studies it is necessary to dissolve the compound in a strong organic solvent (DMSO) or to formulate the drug as a suspension in Tween 80:saline, which is an undesirable drug formulation for human therapy. Recently two analogs of

camptothecin with moderate water solubility have been approved in United States for treatment of advanced ovarian cancer (Hycamtin) and colorectal cancer (Camptosar).

- [05] Other drugs, like camptothecin, that have similar problems are cyclosporin A (CsA), propofol, etoposide and Vitamin E (alpha-tocopherol). Like camptothecin, CsA has within its structure a sterically hindered alcohol, a secondary alcohol in this case. CsA is formulated in a CremophorEL/ethanol mixture.
- [06] An example of a sterically hindered, poorly water-soluble phenol is propofol, an anesthetic. Propofol is formulated for i.v. clinical use as a o/w emulsion. Not only is propofol poorly water soluble, but it also causes pain at the site of injection. The pain must be ameliorated such as with lidocaine. Moreover, because the Propofol is formulated as an emulsion, it is difficult and questionable to add other drugs to the formulation and physical changes to the formulation such as an increase in oil droplet size can lead to lung embolisms, etc.
- [07] U.S. Patent 6,204,257 describes a water-soluble form of alcohol and phenol containing drugs such as camptothecin and propofol. With respect to camptothecin, compounds are phosphonooxymethyl ethers of camptothecin in the form of the free acid and pharmaceutically acceptable salts thereof. The water solubility of the acid and the salts facilitates preparation of pharmaceutical formulations.
- [08] However, the methods of making the water-soluble form of alcohol and phenol containing drugs described in U.S. Patent 6,204,257 are complicated and utilize expensive and carcinogenic reagents. For instance, the synthesis of O-phosphonooxymethylpropofol requires 6 steps as summarized in the reaction scheme below.







[09] It is desirable to have a process that is shorter and does not use carcinogenic or expensive reagents.

## BRIEF SUMMARY OF THE INVENTION


- [10] The present invention relates to a new process of preparing water-soluble phosphonooxymethyl derivatives of alcohol- and phenol-containing drugs, in particular phosphono-O-methyl 2,6-diisopropylphenol disodium salt.
- [11] The present invention is particularly directed to preparing water-soluble phosphonooxymethyl derivatives comprising the steps of:



- [12] wherein R-OH represents an alcohol- or phenol-containing drug, n represents an integer of 1 or 2, R<sup>1</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation, and R<sup>2</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation.
- [13] In a preferred embodiment, 2,6-diisopropylphenol is reacted with bromochloromethane to produce O-chloromethyl-diisopropylphenol.




The O-chloromethyl-diisopropylphenol is reacted with phosphoric acid to produce phosphono-O-methyl 2,6-diisopropylphenol disodium salt.



## DETAILED DESCRIPTION OF THE INVENTION

- [14] The present invention relates to a new process of preparing water-soluble phosphonooxymethyl derivatives of alcohol- and phenol-containing drug, in particular phosphono-O-methyl 2,6-diisopropylphenol disodium salt. Such phosphonooxynethyl derivatives are described in U.S. Patent 6,204,257, which is hereby incorporated by reference in its entirety. The process of the present invention requires only two steps and does not require the carcinogenic and expensive raw materials of the prior art processes. Moreover, chromatography is not required. The process results in high product yields of product of up to 85%, typically about 40 to 85%.
- [15] The invention described herein involves a new process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol containing pharmaceuticals represented by formula I:




- [16] Formula I is the derivative of ROH, wherein ROH represents an alcohol- or phenol-containing drug, such as camptothecin, propofol, etoposide, vitamin E and cyclosporin A. ROH is preferably a phenol-containing pharmaceutical, such as propofol. Also included are some drugs for which injectable forms are not possible

due to their inherent poor water solubility. These include, but are not limited to, danazol, methyltestosterone, iodoquinol, atovaquone, and fluconazole.

- [17] The term n represents an integer of 1 or 2, preferably 1. R<sup>1</sup> is hydrogen or an alkali metal ion including sodium, potassium or lithium or a protonated amine or protonated amino acid or any other pharmaceutically acceptable cation. R<sup>2</sup> is hydrogen or an alkali metal ion including sodium, potassium or lithium or a protonated amine or a protonated amino acid or any other pharmaceutically acceptable cation.


[18] The derivatives according to formula I can be prepared in accordance with the following reaction scheme:




wherein R—OH represents an alcohol- or phenol-containing drug, n represents an integer of 1 or 2, R<sup>1</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation, and R<sup>2</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation.

- [19] In a first step R-OH is reacted with a large excess of bromochloromethane in the presence of a base and tetrahydrofuran (THF). The resulting product is then reacted with an excess of phosphoric acid and a base in a suitable solvent.

[20] An example of the above scheme can be illustrated using 2,6-diisopropylphenol as a starting material. In the first step, 2,6-diisopropylphenol is reacted with bromochloromethane to produce O-chloromethyl-diisopropylphenol.



- [21] In the second step, the O-chloromethyl-diisopropylphenol is reacted with phosphoric acid to produce phosphono-O-methyl 2,6-diisopropylphenol disodium salt.



- [22] More specifically, in the first step, 2,6-diisopropylphenol is reacted with a large molar excess of bromochloromethane in the presence of a base and a suitable solvent, preferably tetrahydrofuran (THF), to yield O-chloromethyl-2,6-diisopropylphenol. The reaction temperature may be about 20°C to about 100 °C, preferably about 25°C to about 65°C.
- [23] The base is preferably an alkali metal hydroxide or alkali metal hydride. Suitable alkali metal hydroxides and hydrides include, but are not limited to, sodium hydride and sodium hydroxide.
- [24] The amount of base is at least about 1.5 moles of base to 1 mole 2,6-diisopropylphenol. The amount of bromochloromethane is at least about 10 moles, preferably about 10 to about 30 moles, of bromochloromethane to 1 mole 2,6-diisopropylphenol. It is contemplated that bromochloromethane may be substituted with iodochloromethane.
- [25] THF may be substituted with other appropriate solvents such as non-protic oxygen containing solvents with strong dissolution power such as glycol ethers.

- [26] In a second step, the O-chloromethyl-2,6-diisopropylphenol is reacted with a molar excess of phosphoric acid and a base in a suitable solvent. At least about 3, preferably about 3 to about 10, typically about 6, moles of phosphoric acid and base are combined with 1 mole of O-chloromethyl-2,6-diisopropylphenol. The reaction temperature is below 100°C, typically about 25°C to about 80°C.
- [27] Suitable solvents include polar aprotic solvents such as acetonitrile, dimethylformamide (DMF), dimethylsulfoxide (DMSO), or N-methylpyrrolidone (NMP). The solvent should be capable of solubilizing the triethylammonium salt of the product. The base is preferably an alkylamine or pyridine or a substituted pyridine derivative. More preferably, the base is triethylamine.
- [28] The solvent is then removed and the residue is dissolved in water and acidified with, for example HCl, to a pH of about 1 to about 2, preferably about 1.5. The product in its free acid form is extracted into MTBE.
- [29] The solvent is then removed such as in vacuo. The residue is dissolved in water, the pH is adjusted to about 8 to about 11.5 with a suitable reagent, for example NaOH, and the solution is extracted with a suitable solvent such as toluene. The solution may then be concentrated. Isopropanol or other suitable solvent may be added and then the product precipitated or recrystallized. Suitable solvents include polar, water miscible organic solvents such as acetone, acetonitrile, an alcohol, THF, or dioxane to yield phosphono-O-methyl 2,6-diisopropylphenol disodium salt.
- [30] Example 1
- [31] Step 1: A four-necked 500 mL round bottom flask was equipped with a mechanical stirrer, nitrogen inlet, condenser and thermometer. It was charged with 17.8 grams (0.10 moles) of 2,6-diisopropylphenol, 200 mL of THF, 8.0 grams (0.20 mole) of sodium hydroxide pellets, and 387 grams (3.0 moles, 194 mL) of bromochloromethane. The reaction mixture was heated to 64°C and held for 2-3 hours until no more 2,6-diisopropylphenol was present as measured by GC. After

cooling to 25°C, the suspension was filtered and the filter cake was washed with THF. The THF was removed by rotary evaporation and the resultant oil was distilled under vacuum (0-1 torr, b.p.=80°C) to give 16.9 grams (0.074 moles, 75% yield) of O-chloromethyl 2,6-diisopropyl phenol.

[32] Step 2: A four-necked 1 L round bottom flask, fitted with a temperature controlling thermocouple, was placed in a heating mantle. The flask was charged with 300 mL acetonitrile followed by triethylamine (48.7 mL, 0.349 mol) and 85% phosphoric acid (18.7 mL, 0.318 mol). O-chloromethyl 2,6-diisopropylphenol (12 g, 0.0529 mol) was then added and the reaction solution was heated to 65°C for 2 h. The reaction was deemed to be complete by the disappearance of starting material as determined by TLC and HPLC. The solution was allowed to cool and the mixture was concentrated under reduced pressure. The residue was dissolved in 500 mL water and acidified with 8N HCl to pH = 1.5. This solution was extracted three times with 500 mL MTBE. The combined organic extracts were washed once with brine and the organic layer was filtered through celite. To the residue was added 60 mL water and 20% NaOH solution was added to pH = 8.6. This solution was washed twice with 50 mL toluene. The aqueous solution was concentrated under reduced pressure to half of the original volume, and 315 mL of isopropanol was added. The mixture was heated to 70°C to dissolve the product then was cooled to 0°C. The white solid that crystallized was isolated by suction filtration, washed one time with 45 mL of isopropanol and was dried in the vacuum oven (30 inches Hg, 45°C) for 48 hours to give 13.1 grams (0.039 moles, 75% yield) of a white solid.

[33] Example 2

[34] Step 1: 2,6-Diisopropylphenol (20 kg, FW (formula weight) = 178, 112 mol, 1 equiv.) is reacted with bromochloromethane (347 kg, FW = 129, 2,682 mol, 24 equiv.) and sodium hydroxide (11 kg, FW = 40, 280 mol, 2.5 equiv.) in tetrahydrofuran (108 kg, FW = 72, 1,498 mol, 13.3 equiv.) at reflux for approximately 1.5 hours. After cooling to 20 °C, the reaction mixture is quenched with water (87

kg). The organic layer is collected and washed with 15% sodium chloride aqueous solution (78 kg) twice. The organic layer is collected again after the layer separation, and the solvents are distilled from the organic layer to afford a crude oil. The crude oil is distilled by simple distillation to yield a purified chloromethyl(2,6-diisopropylphenyl)ether (FW = 227) as a light yellow oil.

- [35] Step 2: Chloromethyl(2,6-diisopropylphenyl)ether (20 kg, FW = 227, 88.20 mol, 1 equiv.) is reacted with phosphoric acid (81 kg, 85 %, FW = 98, 705 mol, 8 equiv.) and triethylamine (89 kg, FW = 101, 883 mol, 10 equiv.) in acetonitrile (200 kg, FW = 41, 4,872 mol, 55 equiv.) at approximately 75 °C for 3 hours. The reaction mixture is cooled and concentrated under vacuum. The resulting slurry is dissolved in water. The pH of the mixture is adjusted to 1.5 with concentrated hydrochloric acid. The acidified mixture is extracted twice with toluene. The two organic extracts are combined and washed with water once. The organic solution is concentrated under vacuum. The resulting oil is mixed with purified water, USP. The pH of the mixture is adjusted to 11 with 50 % sodium hydroxide aqueous solution. The aqueous mixture is washed with toluene twice. The aqueous mixture is then partially concentrated under vacuum to about 40 to 50 % of the original volume. Isopropyl alcohol (525 kg) is added to the concentrated aqueous solution at 70 °C, then cooled to 0 °C to crystallize the product. The solid is collected by filtration and dried under vacuum to afford phosphono-O-methyl 2,6-diisopropylphenol disodium salt ( $C_{13}H_{19}Na_2O_3P$ , FW = 332)

[36] Example 3

- [37] Step 1: A four-necked 500 mL round bottom flask was equipped with a mechanical stirrer, nitrogen inlet, condenser and thermometer. It was charged with 8.9 grams (0.05 moles) of 2,6-diisopropylphenol, 100 mL of THF and 4.0 grams (0.10 mole) of sodium hydroxide pellets. The resultant green suspension was heated to 60-65°C and held for one hour. The reaction mixture was cooled to 30°C and 100 mL (199 grams, 1.54 moles) bromochloromethane was added and heating was resumed. The reaction

mixture was held at 64°C for 2-3 hours until no more 2,6-diisopropylphenol was present as measured by GC. After cooling to 25°C, the suspension was filtered through Celite and the filter cake was washed with THF. The THF was removed by rotary evaporation and the resultant oil was distilled under vacuum (0-1 torr, b.p.=80°C) to give 9.6 grams (0.042 moles, 85% yield) of O-chloromethyl 2,6-diisopropyl phenol.


- [38] Step 2: A four-necked 1 L round bottom flask, fitted with a temperature controlling thermocouple, was placed in a heating mantle. The flask was charged with 300 mL acetonitrile followed by triethylamine (48.7 mL, 0.349 mol) and 85% phosphoric acid (18.7 mL, 0.318 mol). O-chloromethyl 2,6-diisopropylphenol (12 g, 0.0529 mol) was then added and the reaction solution was heated to 65°C for 2 h. The reaction was deemed to be complete by the disappearance of starting material as determined by TLC and HPLC. The solution was allowed to cool and the mixture was concentrated under reduced pressure. The residue was dissolved in 500 mL water and acidified with 8N HCl to pH = 1.5. This solution was extracted three times with 500 mL MTBE. The combined organic extracts were washed once with brine and the organic layer was filtered through celite. One equivalent of TEA was added and the solution was concentrated under reduced pressure. To the residue was added 60 mL water and 20% NaOH solution was added to pH = 8.6. This solution was washed twice with 50 mL toluene. The aqueous solution was concentrated under reduced pressure. Water (30 ml) was added and the solution was cooled in an ice bath. Acetone (300mL) was added dropwise. The resulting mixture was cooled in the refrigerator overnight. The mixture was then cooled in an ice bath for 1 hour, then the solids were filtered. The white solid was dried in the vacuum oven (30 inches Hg, 45°C) for 48 hours to give 7.50 grams (0.023 moles, 43% yield) of a white solid.
- [39] Example 4
- [40] 2,6-diisopropylphenol was treated with bromochloromethane in the presence of sodium hydroxide and THF to give an 85% yield of O-chloromethyl-2,6-

diisopropylphenol, which was purified by vacuum distillation. Treatment of O-chloromethyl-2,6-diisopropylphenol with phosphoric acid and triethylamine in acetonitrile followed by solvent removal, dissolution in methanol, pH adjustment and precipitation with acetone gave an 85% yield of phosphono-O-methyl 2,6-diisopropylphenol disodium salt.

- [41] While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention.

**We Claim:**

1. A process for preparing water-soluble phosphonooxymethyl derivatives comprising the steps of:




wherein R—OH represents an alcohol- or phenol-containing drug, n represents an integer of 1 or 2, R<sup>1</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation, and R<sup>2</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation.


2. The process of claim 1 wherein R—OH represents camptothecin, propofol, etoposide, vitamin E, or cyclosporin A.
3. The process of claim 1 wherein n is 1.
4. The process of claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from the group consisting of hydrogen, sodium, potassium, lithium, a protonated amine, and a protonated amino acid.
5. The process of claim 1 wherein in the first step, R—OH is reacted with a molar excess of bromochloromethane in the presence of a base and a suitable solvent.
6. The process of claim 1 wherein in the first step, R—OH is reacted with a molar excess of iodochloromethane in the presence of a base and a suitable solvent

7. The process of claim 5 wherein the base is an alkali metal hydroxide or alkali metal hydride.
8. The process of claim 7 wherein the base is sodium hydroxide or sodium hydride.
9. The process of claim 5 wherein the solvent is an aprotic or a non-protic oxygen containing solvent.
10. The process of claim 9 wherein the solvent is tetrahydrofuran.
11. The process of claim 5 wherein at least about 1.5 moles of base is present for every 1 mole of R—OH.
12. The process of claim 5 wherein at least about 10 moles of bromochloromethane is present for every one mole of R—OH.
13. The process of claim 12 wherein about 10 to about 30 moles of bromochloromethane is present for every one mole of 2,6-diisopropylphenol.
14. The process of claim 1 wherein R—OH is 2,6-diisopropylphenol.
15. The process of claim 1 wherein the reaction temperature in the first step is about 25°C to about 65°C.
16. The process of claim 1 wherein in the second step, the R—O-CH<sub>2</sub>Cl is reacted with a molar excess of phosphoric acid and a base in a suitable polar aprotic solvent.
17. The process of claim 16 wherein at least about 3 moles of phosphoric acid are combined with 1 mole of R—O-CH<sub>2</sub>Cl.

18. The process of claim 17 wherein about 3 to about 10 moles of phosphoric acid is present per mole of R—O—CH<sub>2</sub>Cl.
19. The process of claim 1 wherein the reaction temperature in the second step is below 100°C,
20. The process of claim 19 wherein the reaction temperature is about 25°C to about 80°C.
21. The process of claim 16 wherein the polar aprotic solvent is selected from the group consisting of acetonitrile, dimethylformamide, dimethylsulfoxide, or N-methylpyrrolidone.
22. The process of claim 16 wherein the base is an alkylamine or pyridine or a substituted pyridine derivative.
23. The process of claim 22 wherein the base is triethylamine.
24. The process of claim 1 wherein the pH of the second step is initially maintained at about 1 to about 2, and then adjusted to about 8 to about 11.5.
25. A process for preparing water-soluble phosphonooxymethyl derivatives comprising reacting 2,6-diisopropylphenol with bromochloromethane to produce O-chloromethyl-diisopropylphenol:



then reacting the O-chloromethyl-diisopropylphenol with phosphoric acid to produce phosphono-O-methyl 2,6-diisopropylphenol disodium salt



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number  
**WO 2003/059255 A3**

(51) International Patent Classification<sup>7</sup>: A61K 31/66 (74) Agent: WOLFFE, Susan, A.; Banner & Witcoff, Ltd., 1001 G Street, N.W., Washington, DC 20001-4597 (US).

(21) International Application Number:  
PCT/US2002/040748

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:  
20 December 2002 (20.12.2002)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:  
— with international search report

(26) Publication Language: English

(88) Date of publication of the international search report:  
19 February 2004

(30) Priority Data:  
60/341,867 21 December 2001 (21.12.2001) US



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): GUILFORD PHARMACEUTICALS, INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BONNEVILLE, George [US/US]; 5711 Greenleaf Road, Baltimore, MD 21210 (US). DELAHANTY, Greg [US/US]; 22 Enchanted Hills Road, Apt. 203, Owings Mills, MD 21117 (US). WALZ, Andrew, J. [US/US]; 122 Morgan Elis Way, Baltimore, MD 21206 (US).

(54) Title: PROCESS FOR PREPARING WATER-SOLUBLE PHOSPHONOXYMETHYL DERIVATIVES OF ALCOHOL AND PHENOL



WO 2003/059255 A3

(57) Abstract: A process for making water-soluble phosphonoxyethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A. In particular, the process for preparing water-soluble phosphonoxyethyl derivatives comprises the steps of Formula (i) and Formula (ii); R-OH represents an alcohol- or phenol-containing drug, n represents an integer of 1 or 2, R<sup>1</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation, and R<sup>2</sup> is hydrogen, an alkali metal ion, or a pharmaceutically acceptable cation.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US02/40748

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 31/66  
US CL : 514/75

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 514/75; 558/70, 87

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
WEST, CAS Online

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6,204,257 A (STELLA et al) 20 March 2001 (20.03.2001), see entire document.	1-25

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"E"	earlier application or patent published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search

30 September 2003 (30.09.2003)

Date of mailing of the international search report

22 OCT 2003

Name and mailing address of the ISA/US  
Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
Facsimile No. (703)305-3230

Authorized office:  
David Lukton  
Telephone No. 703-308-0196